With the recent renaming of NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and the evolving landscape of treatment, when is the right time to use resmetirom? In this episode, we explore how this thyroid hormone receptor-β agonist is changing the management of MASLD, particularly in patients with significant fibrosis. We also break down non-invasive testing methods—for instance, elastography, CAP scores, (FibroScan), ELF score, and FIB4—to help stage patients and guide treatment decisions.

Tune in as we discuss the science, clinical guidelines, and real-world considerations for incorporating resmetirom into patient care!

Please feel free to send any questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com 

Thank you for listening!